Welcome to our dedicated page for Surrozen SEC filings (Ticker: SRZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Surrozen, Inc. (SRZN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Surrozen uses these filings to report financial results, material events, executive appointments, collaboration changes, and other information relevant to its development of Wnt pathway–modulating therapeutics for severe eye diseases.
Current reports on Form 8-K are an important source of timely updates for SRZN. For example, Surrozen has filed 8-Ks to announce quarterly financial results, describe the appointment of a Chief Financial Officer and associated compensation arrangements, and disclose the termination of a collaboration agreement with TCGFB, Inc. for antibody discovery services. These filings often reference attached press releases that provide more detailed narrative on business performance and pipeline progress.
Investors can also use Surrozen’s periodic reports, such as its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, to review consolidated financial statements, research and development spending, and risk factor discussions. The company’s forward-looking statements in press releases explicitly point readers to these reports for a fuller description of risks related to its discovery, preclinical and potential clinical activities, funding needs, and collaboration structures.
On Stock Titan, Surrozen’s SEC filings are complemented by AI-powered summaries that highlight key points from lengthy documents, helping users quickly identify items such as revenue sources, operating expenses, non-cash fair value changes, and material agreements. Filings related to equity compensation and inducement grants under Nasdaq Listing Rule 5635(c)(4) can help users understand Surrozen’s use of stock options and warrants, while 8-K items on collaborations and licenses provide insight into related-party transactions and strategic partnerships, including the Boehringer Ingelheim agreement for SZN-413. Together, these filings offer a structured view of Surrozen’s financial condition, governance decisions, and development activities.
Surrozen, Inc. filed a prospectus to offer up to $50,000,000 of common stock through an at‑the‑market sales agreement with TD Securities (USA) LLC (TD Cowen). The company may sell shares from time to time on Nasdaq or other trading markets under the Sales Agreement dated March 23, 2026.
The prospectus states an assumed reference price of $25.15 per share (last reported sale price on March 20, 2026) and illustrates that up to 11,762,608 shares could be issued if the full $50,000,000 aggregate amount is sold at that price. Proceeds are intended for working capital and general corporate purposes, and TD Cowen may receive up to 3.0% of gross proceeds as compensation.
Surrozen, Inc. reported open-market share purchases by affiliated TCG Crossover funds. On March 23–24, entities associated with TCG Crossover Fund II and Fund III bought a combined 121,881 shares of Surrozen common stock in multiple open-market transactions at prices around $24.90 and $24.69 per share.
The Form 4 shows these positions as indirect holdings, with the shares held of record by TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P. After these buys, the reporting entities disclose indirect ownership levels between 683,218 and 736,554 shares across the noted positions, reinforcing their status as significant, greater-than-10% shareholders.
Surrozen, Inc. files a shelf registration to offer up to $200,000,000 of securities. The registration on March 23, 2026 establishes a base prospectus that permits the company to offer common stock, preferred stock, debt securities and warrants from time to time under prospectus supplements.
The prospectus states proceeds are to be used for working capital and general corporate purposes and may be used for strategic investments or acquisitions; specific terms, prices and underwriters will be set in later prospectus supplements. Surrozen identifies itself as a smaller reporting company and notes its common stock and public warrants trade on the Nasdaq Capital Market under the symbols SRZN and SRZNW.
Surrozen, Inc. files its annual report describing a shift to an ophthalmology-focused pipeline built on Wnt-pathway modulation. The company highlights preclinical eye candidates SZN-8141 and SZN-8143 for diabetic macular edema, wet age-related macular degeneration and uveitic macular edema, all based on its SWAP antibody platform.
Surrozen’s Fzd4-targeted antibody SZN-413 is partnered with Boehringer Ingelheim; Boehringer’s 2024 advancement decision triggered a $10.0 million milestone, and a 2026 toxicology milestone entitles Surrozen to an additional $5.0 million. The company also discontinued liver candidate SZN-043 in severe alcohol-associated hepatitis to focus resources on eye diseases.
Surrozen reported a much larger 2025 net loss but ended the year with significantly more cash and a sharper focus on ophthalmology. Net loss widened to $242.0 million, or ($32.37) per share, from $63.6 million, largely due to non-cash losses tied to a 2025 private placement and related tranche and warrant liabilities.
Cash and cash equivalents rose to $89.2 million as of December 31, 2025, up from $34.6 million a year earlier, helped by equity sales and warrant exercises in early 2026. Total 2025 revenue was $3.5 million, down from $10.7 million, while research and development and general and administrative expenses increased to $29.4 million and $16.2 million, respectively. The company advanced retinal programs SZN-8141 and SZN-8143, expects to file an IND for SZN-8141 in the second half of 2026, and earned a $5.0 million milestone from Boehringer Ingelheim under the SZN-413 partnership, which also includes up to $586.5 million in potential future milestones.
Surrozen, Inc. (SRZN) reported insider buying by affiliated investment funds. TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P., both 10% holders, executed a series of open-market purchases of Common Stock on March 12–16, 2026, totaling 48,997 shares according to the filing’s transaction summary.
The trades were made at prices between 24.8769 and 24.9857 per share and are reported as indirect holdings. TCG Crossover GP II, LLC and TCG Crossover GP III, LLC act as general partners to the funds, and Chen Yu may be deemed to share voting, investment and dispositive power over these securities.
Surrozen, Inc. executive Li Yang received new equity awards consisting of stock options and restricted stock units. On February 17, 2026, Yang was granted options to purchase 100,950 shares of common stock at an exercise price of $0.00 per share and 100,950 restricted stock units.
The stock options vest over four years in 48 equal monthly installments starting February 1, 2026, conditioned on continued service. The RSUs vest in four equal annual installments beginning February 1, 2026, also subject to continued service. These awards represent direct ownership incentives rather than open-market share purchases.
Williams Charles O reported acquisition or exercise transactions in this Form 4 filing.
Surrozen, Inc. reported that its Chief Operating Officer, Charles O. Williams, received two new equity awards. On February 17, 2026, he was granted employee stock options covering 102,900 shares of common stock at a grant price of $0.00 per share. These option shares vest over four years in 48 equal monthly installments starting February 1, 2026, conditioned on continued service. He was also granted 102,900 restricted stock units, each representing one share of common stock, which vest in four equal annual installments beginning February 1, 2026, also subject to continued service.
Surrozen, Inc. reported that Chief Executive Officer Craig C. Parker received new equity awards. On February 17, 2026, he was granted an employee stock option covering 242,200 shares of common stock at an exercise price of $0.0000 per share, held as direct ownership.
The option vests over four years in 48 equal monthly installments starting from February 1, 2026, conditioned on continued service. Parker was also granted 242,200 restricted stock units, each representing one share of common stock. These RSUs vest in four equal annual installments beginning on February 1, 2026, also subject to continued service.